Masamitsu Onda
- Oncology top 10%
- Cancer-related Molecular Pathways 9
- Cancer Research top 10%
- Cancer Genomics and Diagnostics 5
- Cell Biology top 10%
- Molecular Biology top 10%
- Cancer-related gene regulation 5
- Gene expression and cancer classification 5
- RNA Research and Splicing 5
- Pathology and Forensic Medicine top 10%
- Genetic factors in colorectal cancer 9
-
- Thyroid Cancer Diagnosis and Treatment 6
-
- Hair Growth and Disorders 5
- Co-authors
- Mitsuru EmiHisaki NagaiTakemitsu NagahataJunko AkaishiTakashi FujimotoShinichi AsakaM. EmiKenji Ogawa
- Cited by
- OncologyCancer ResearchCell Biology
- Partner nations
- JapanUnited StatesDenmark
In The Last Decade
Masamitsu Onda
42 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 87
- Oncology 341
- Cancer Research 186
- Cell Biology 192
- Molecular Biology 730
- Pathology and Forensic Medicine 137
Countries citing papers authored by Masamitsu Onda
This map shows the geographic impact of Masamitsu Onda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masamitsu Onda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masamitsu Onda more than expected).
Fields of papers citing papers by Masamitsu Onda
This network shows the impact of papers produced by Masamitsu Onda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masamitsu Onda. The network helps show where Masamitsu Onda may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Masamitsu Onda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2022 | 1 | |
| 3 | 2018 | 1 | |
| 4 | 2011 | 2 | |
| 5 | 2008 | 25 | |
| 6 | 2006 | 16 | |
| 7 | 2006 | 86 | |
| 8 | 2005 | 42 | |
| 9 | 2005 | 47 | |
| 10 | 2005 | 33 | |
| 11 | 2004 | 56 | |
| 12 | 2004 | 59 | |
| 13 | 2004 | 8 | |
| 14 | 2004 | 39 | |
| 15 | 2004 | 34 | |
| 16 | 2003 | 103 | |
| 17 | 2002 | 1 | |
| 18 | Instability of X chromosome methylation in aberrant crypt foci of the human colon. | 2000 | 28 |
| 19 | 1998 | 8 | |
| 20 | 1995 | 4 |
About Masamitsu Onda
Masamitsu Onda is a scholar working on Urology, Oncology and Pathology and Forensic Medicine, having authored 43 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (9 papers), Genetic factors in colorectal cancer (9 papers), Thyroid Cancer Diagnosis and Treatment (6 papers), Hair Growth and Disorders (5 papers), Cancer Genomics and Diagnostics (5 papers), Cancer-related gene regulation (5 papers), Gene expression and cancer classification (5 papers) and RNA Research and Splicing (5 papers). The work is most often cited by research in Oncology (341 citations), Cancer Research (186 citations) and Cell Biology (192 citations). Masamitsu Onda has collaborated with scholars based in Japan, United States and Denmark. Frequent co-authors include Mitsuru Emi, Hisaki Nagai, Takemitsu Nagahata, Junko Akaishi, Takashi Fujimoto, Shinichi Asaka, M. Emi, Kenji Ogawa, Seiichi Takenoshita and Akira Yoshida. Their work appears in journals such as Cancer, Oncogene and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.